Radioterapia de salvamento para pacientes con cáncer de próstata: experiencia en el Instituto Nacional de Cancerología

Autores/as

  • Rosalba Ospino Instituto Nacional de Cancerología
  • Juan Galvis Instituto Nacional de Cancerología
  • Jorge Rugeles Instituto Nacional de Cancerología
  • Angélica Mojica Instituto Nacional de Cancerología
  • José Esguerra Instituto Nacional de Cancerología

Palabras clave:

Neoplasias de la próstata, radioterapia, prostatectomía, antígeno prostático específico

Resumen

Objetivo: Describir la experiencia con radioterapia de salvamento en pacientes que presentaron recaída bioquímica, posterior a una prostatectomía radical, en el Instituto Nacional de Cancerología (INC).
Métodos: Estudio observacional retrospectivo tipo serie de casos. Se recolectaron los casos atendidos entre 2003 y 2007. Se describió la información mediante estadística descriptiva, empleando frecuencias relativas, así como medidas de tendencia central y de dispersión. Se describió la supervivencia libre de enfermedad.
Resultados: Un total de 40 pacientes que recibieron radioterapia de salvamento por recaída bioquímica fueron incluidos. La recaída posprostatectomía se presentó antes de dos años en el 65% de los pacientes. La mediana de PSA prerradioterapia en el presente estudio fue de 0,9 ng/ml. El 87,5% de los pacientes fueron tratados con radioterapia conformacional 3D. El 97,5% de los pacientes recibieron una dosis total de 66 Gy. La supervivencia libre de enfermedad según la clasificación de riesgo de la enfermedad fue de 2,29 años, con una mediana de seguimiento de 28,5 meses. Dos pacientes presentaron recaída bioquímica posterior a la radioterapia de salvamento.
Conclusiones: La radioterapia de salvamento se muestra como una intervención apropiada en pacientes con cáncer de próstata que presentaron recaída bioquímica después de prostatectomía radical; el 94% de los pacientes tratados con radioterapia de rescate en el INC entre 2003 y 2007 están libres de recaída.

Biografía del autor/a

Rosalba Ospino, Instituto Nacional de Cancerología

Grupo de Radioterapia, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia

Juan Galvis, Instituto Nacional de Cancerología

Grupo de Radioterapia, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia

Jorge Rugeles, Instituto Nacional de Cancerología

Grupo de Radioterapia, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia

Angélica Mojica, Instituto Nacional de Cancerología

Grupo de Radioterapia, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia

José Esguerra, Instituto Nacional de Cancerología

Grupo de Radioterapia, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia

Referencias bibliográficas

Penson DF, Chan JM. Prostate cancer. J Urol. 2007;177:2020-9.

https://doi.org/10.1016/j.juro.2007.01.121

Forman JD, Meetze K, Pontes E, et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol. 1997;158:1436-9.

https://doi.org/10.1016/S0022-5347(01)64235-6

Lowes LE, Lock M, Rodríguez G, et al. Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy. Clin Transl Oncol. 2012;14:150-6.

https://doi.org/10.1007/s12094-012-0775-5

Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-65.

https://doi.org/10.1016/S0094-0143(05)70163-4

Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005;2:174-82.

https://doi.org/10.1038/ncpuro0145

Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-7.

https://doi.org/10.1001/jama.281.17.1591

Sia M, Pickles T, Morton G, et al. Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Can Urol Assoc J. 2008;2:500-7.

https://doi.org/10.5489/cuaj.916

D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-83.

https://doi.org/10.1093/jnci/djg043

Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576-81.

https://doi.org/10.1016/S0025-6196(11)62406-3

Shekarriz B, Upadhyay J, Wood DP, Jr., et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology. 1999;54:1044-8.

https://doi.org/10.1016/S0090-4295(99)00351-9

Bolla M, van PH, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-8.

https://doi.org/10.1016/S0140-6736(05)67101-2

Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-35.

https://doi.org/10.1001/jama.296.19.2329

Wiegel T, Störkel S, Bottke D, et al. Prostate cancer: Phase III study of adjuvant radiotherapy versus wait and see: Impact of pathologic review on analysis. JCO. 2009;27:2924-30.

https://doi.org/10.1200/JCO.2008.18.9563

Choo R, Kawakami J, Siemens R, et al. Two different perspectives in the management of pT3 and/or marginpositive prostate cancer after radical prostatectomy. BJU Int. 2006;98:773-6.

https://doi.org/10.1111/j.1464-410X.2006.06423.x

Boccon, L. pT3 prostate cancer: the case for salvage (as opposed to adjuvant) radiation therapy. Eur Urol Supp. 2007;6:511-72.

https://doi.org/10.1016/j.eursup.2007.01.026

Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51-60.

https://doi.org/10.1016/S0167-8140(01)00302-4

Neuhof D, Hentschel T, Bischof M, et al. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:1411-7.

https://doi.org/10.1016/j.ijrobp.2006.11.024

Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-32.

https://doi.org/10.1001/jama.291.11.1325

Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-41.

https://doi.org/10.1200/JCO.2006.08.9607

Trock BJ, Han M, Freedland SJ, et al. Prostate cancerspecific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760-9.

https://doi.org/10.1001/jama.299.23.2760

Michalski J, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76:361-8.

https://doi.org/10.1016/j.ijrobp.2009.02.006

Moreira DM, Banez LL, Presti JC, Jr., et al. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010;105:28-33.

https://doi.org/10.1111/j.1464-410X.2009.08684.x

Umezawa R, Ariga H, Ogawa Y, et al. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostatespecific antigen < 1.0 ng/ml. Radiat Oncol. 2011;6:150.

https://doi.org/10.1186/1748-717X-6-150

Siegmann A, Bottke D, Faehndrich J, et al. Salvage radiotherapy after prostatectomy - What is the best time to treat? Radiother Oncol. 2012;103:239-43.

https://doi.org/10.1016/j.radonc.2011.10.024

Martin T, Wenz F, Bohmer D, et al. Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy. Urologe A. 2010;49:216-20. [Artículo en alemán].

Wenz F, Martin T, Bohmer D, et al. The German S3 guideline prostate cancer: aspects for the radiation oncologist. Strahlenther Onkol. 2010;186:531-4.

https://doi.org/10.1007/s00066-010-2193-3

Budiharto T, Perneel C, Haustermans K, et al. A multiinstitutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol. 2010;97:474-9.

https://doi.org/10.1016/j.radonc.2010.07.008

Pinto F, Prayer-Galetti T, Gardiman M, et al. Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol Int. 2006;76:202-8.

https://doi.org/10.1159/000091619

Chun FK, Graefen M, Zacharias M, et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol. 2006;24:273-80.

https://doi.org/10.1007/s00345-006-0058-2

Swindle P, Eastham JA, Ohori M, et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 2005;174:903-7.

https://doi.org/10.1097/01.ju.0000169475.00949.78

Salomon L, Anastasiadis AG, Antiphon P, et al. Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int. 2003;70:291-6.

https://doi.org/10.1159/000070138

Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-4.

https://doi.org/10.1097/01.ju.0000134888.22332.bb

Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multiinstitutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008;72:1298-302.

https://doi.org/10.1016/j.urology.2008.05.057

Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys. 2009;73:1009-16.

https://doi.org/10.1016/j.ijrobp.2008.06.1922

Ward JF, Zincke H, Bergstralh EJ, et al. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004;172:2244-8.

https://doi.org/10.1097/01.ju.0000145262.34748.2b

Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002;20:3199-205.

https://doi.org/10.1200/JCO.2002.01.086

Lightner DJ, Lange PH, Reddy PK, et al. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;144:921-6.

https://doi.org/10.1016/S0022-5347(17)39623-4

Van den Ouden D, Bentvelsen FM, Boeve ER, et al. Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol. 1993;72:489-94.

https://doi.org/10.1111/j.1464-410X.1993.tb16183.x

Ospino R, Cendales R, Alonso CE. Braquiterapia de alta tasa de dosis en pacientes con cáncer de próstata. Rev. Colomb. Cancerol. 2008;12:30-3.

Peterson JL, Buskirk SJ, Heckman MG, et al. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol. 2009;93:203-6.

https://doi.org/10.1016/j.radonc.2009.08.035

Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003;170:1833-7.

https://doi.org/10.1097/01.ju.0000091835.80547.a4

Cómo citar

[1]
Ospino, R. et al. 2012. Radioterapia de salvamento para pacientes con cáncer de próstata: experiencia en el Instituto Nacional de Cancerología. Revista Colombiana de Cancerología. 16, 3 (sep. 2012), 145–153.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

01-09-2012

Número

Sección

Artículos de investigación/originales